Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.

Araxes Pharma LLC is an American private company located in La Jolla, CA. The firm develops drugs for the treatment of cancer and other diseases.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Aventis Pharma Deutschland GmbH produces pharmaceutical products. It offers prescription drugs, human vaccines, and therapeutic proteins businesses. Aventis Pharma Deutschland plans and designs plants and process control systems in the areas of active ingredients production and finished drugs. The company is headquartered in Frankfurt am Main, Germany.

Chengdu Xianxian Biological Technology Co., Ltd., established on 2013-06-25, Business scope includes biological,Medical technology research and development,Agricultural Technology Development,technical consulting;R&D and sales of computer software and hardware;Electronic technology development;New material technology development;Sales:electronic product,Chemical products and raw materials(Free of Hazardous Chemicals),metal products,Instrumentation,building materials,Office supplies and consumables,daily necessities,Leather,bags;account Serive;Exhibition display service;Enterprise Marketing Planning;Business Management Consulting;Advertising Design,make,Proxy and release;Business Consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Pantarhei Bioscience BV (PRB) is a limited liability company (Besloten Vennootschap) located in the Netherlands focussing on the development of innovative concepts for woman’s health and hormone-related cancer treatments. PRB has founded a subsidiary company – Pantarhei Oncology (PRO) – to develop treatments for Endocrine Cancer. PRB has developed a product pipeline based on its ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments and diseases such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are breast cancer, prostate cancer and ovarian cancer . PRB develops patent protected new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model of the Pantarhei companies is based on creating intellectual property (IP) of new concepts ad inventions, in-house project management and outsourcing of all research and development activities. After successful PoC, data and IP are licensed out to a licensee or partner for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.

Sichuan Baoshengkang Pharmaceutical Co., Ltd., established on 2003-10-28, Business scope includes wholesale:biochemical drug,Chinese herbal medicine,Chinese Herbal Medicine,Biological product(Free of prophylactic biologicals),Chemical API,Antibiotic API,Chinese patent medicine,Chemicals,antibiotic preparation,medical instruments;Medical Research;Import and export,Technology Import and Export;Wholesale and retail:Clothing and shoes,knitted goods,Leather,Disinfectant,lubricating oil,cosmetic,plastic products,sporting goods,Office Supplies,Chemical Products(Does not contain dangerous goods),photographic equipment,Audio equipment,computer,Software and Auxiliary Equipment,hardware products,steel,building materials,daily necessities,lamps,household appliances,electronic product,communication equipment(Does not include radio transmitters),Instrumentation,Electrical Equipment;Business Management Consulting;design,make,Agent publishes advertisement;Warehousing Services(Does not contain dangerous goods);shipping agent;Exhibition service;Conference Services;food business. (Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Knoll AG, part of BASF SE, is a company headquartered in Haren, Germany, that develops pharmaceuticals.

Chengdu Essenke Biotechnology Co., Ltd., established on 2015-05-05, Business scope includes biotechnology,Medical technology research and development;Agricultural Technology Development,technical consulting;research and development,Sales of computer software and hardware;Electronic information technology development;New material technology development;sell electronics,Chemical raw materials and products(Free of Hazardous Chemicals),metal products,Instrumentation,building materials(Free of Hazardous Chemicals),Office supplies and consumables,daily necessities,Leather,bags;Conference and exhibition service;Enterprise Marketing Planning;Business Management Consulting;design,make,Acting and publishing advertisements(except for balloon ads);business inquiries.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Chengdu Speika Technology Co., Ltd., established on 2016-04-19, Business scope includes research and development,Sales:Computer hardware and software,electronic product;Computer Network Technology Consulting Services;Advertising Design,make,acting,release(Excluding balloon advertisements and fixed-form print advertisements);Cultural exchange event planning;Enterprise Marketing Planning;Conference and exhibition service;Business Management Consulting;Business Consulting;Sales:Office supplies and consumables,sporting goods,daily necessities,furniture,tea set,Stationery,lamps,household appliances,digital product.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

D. E. Shaw Research ("DESRES") is engaged in scientific research and technological development in the field of computational biochemistry, including - The design of novel algorithms and machine architectures for high-speed molecular dynamics (MD) simulations of proteins and other biological macromolecules. In particular, they have designed and constructed a specialized supercomputer called Anton, which executes such simulations orders of magnitude faster than was previously possible, along with a number of software tools and techniques that facilitate their execution and analysis. - The use of long MD simulations to study the structural changes underlying biological phenomena that occur on time scales far in excess of those previously accessible to computational study, with the ultimate aim of significantly advancing the process of drug discovery. They have been investigating, for example, the mechanisms of certain cellular receptors, transport proteins, and enzymes relevant to the understanding and potential treatment of cancer, diabetes, and other diseases. Their research team includes computational chemists and biologists, computer scientists and applied mathematicians, and computer architects and engineers, all working collaboratively under the leadership of its chief scientist, David Shaw.